Actualités

Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) announced better-than-expected revenue in Q2 CY2026, with sales up 47.7% year on year to $481 million. The company’s full-year revenue guidance of $1.87 billion at the midpoint came in 5.9% above analysts’ estimates. Its non-GAAP profit of $2.28 per share was 25.5% above analysts’ consensus estimates.

In early August 2026, Halozyme Therapeutics, Inc. reported record second‑quarter results, with revenue rising to US$481 million and net income to US$229.91 million, and raised its full‑year 2026 revenue guidance to a range of US$1.84 billion to US$1.91 billion. The company also accelerated capital returns by completing US$750 million of share repurchases under a 2024 authorization and buying an additional US$175.01 million of stock under a new 2026 program, while signing five new...

Halozyme earnings beat and guidance hike reshape the story Halozyme Therapeutics (HALO) just put fresh numbers on the table, reporting second quarter 2026 results, raising full year revenue guidance and updating progress on its share repurchase programs. For the quarter ended June 30, 2026, revenue was reported at US$481 million compared with US$325.72 million for the same period a year earlier. Net income for the quarter was US$229.91 million compared with US$165.16 million a year ago. Basic...

Halozyme stock rocketed to a record high Friday as its newer Enhanze-tied products start driving incremental growth.

Stock Market Today: The Dow Jones index rises Friday ahead of a pivotal July jobs report. AI name Cloudflare stock soars on earnings.

Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 47.7% year on year to $481 million. The company’s full-year revenue guidance of $1.87 billion at the midpoint came in 5.9% above analysts’ estimates. Its non-GAAP profit of $2.28 per share was 25.5% above analysts’ consensus estimates.

This medical technology name has a patented method of drug delivery. Halozyme stock recently hit a record high with earnings due out soon.

Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

ABSCI CORP (ABSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Myriad Genetics trades near 0.4x sales as investors weigh cheap valuation against 2026 launch execution and uneven segment performance.

Halozyme Therapeutics (HALO) posted stronger-than-expected Q1 results, with revenue beating consensu

ANI (ANIP) delivered earnings and revenue surprises of +60.16% and +15.61%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

ImmunityBio (IBRX) delivered earnings and revenue surprises of -12.50% and +7.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the most profitable biotech stocks to buy now. On April 13, TD Cowen reaffirmed its Buy rating and $96 price target for Halozyme Therapeutics, Inc. (NASDAQ:HALO). The firm forecasts Halozyme to continue to outperform expectations and enhance guidance due to strong growth catalysts such as Vyvgart Hytrulo, Darzalex Faspro, […]

Halozyme Therapeutics has seen its modelled Fair Value price target updated to $85.78 from $84.89, reflecting a modest recalibration in the latest assumptions. Analysts linking this change to current research point to royalty streams, ENHANZE collaborations, and acquired subcutaneous platforms as key factors shaping views on valuation and execution risk. As you read on, you will see how these moving pieces feed into the evolving narrative around Halozyme and what to watch next in the...

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most undervalued biotech stocks to buy right now. Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on April 7 that its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals Incorporated. According to the collaboration, Vertex has licensed Halozyme Therapeutics’ (NASDAQ:HALO) Hypercon™ technology […]

Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.